nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ERBB2—ovarian cancer	0.297	0.618	CbGaD
Afatinib—EGFR—ovarian cancer	0.14	0.292	CbGaD
Afatinib—EGFR—Docetaxel—ovarian cancer	0.0958	0.376	CbGbCtD
Afatinib—ABCG2—Topotecan—ovarian cancer	0.0442	0.173	CbGbCtD
Afatinib—ABCB1—ovarian cancer	0.0427	0.0889	CbGaD
Afatinib—ABCG2—Paclitaxel—ovarian cancer	0.0219	0.0858	CbGbCtD
Afatinib—ABCG2—Carboplatin—ovarian cancer	0.0206	0.0807	CbGbCtD
Afatinib—ABCB1—Topotecan—ovarian cancer	0.0159	0.0625	CbGbCtD
Afatinib—ABCG2—Docetaxel—ovarian cancer	0.0158	0.062	CbGbCtD
Afatinib—ABCG2—Doxorubicin—ovarian cancer	0.0118	0.0462	CbGbCtD
Afatinib—ABCB1—Vinorelbine—ovarian cancer	0.0112	0.044	CbGbCtD
Afatinib—ABCB1—Paclitaxel—ovarian cancer	0.00789	0.0309	CbGbCtD
Afatinib—ABCB1—Docetaxel—ovarian cancer	0.0057	0.0224	CbGbCtD
Afatinib—ERBB2—oviduct—ovarian cancer	0.00481	0.0801	CbGeAlD
Afatinib—ABCB1—Doxorubicin—ovarian cancer	0.00425	0.0167	CbGbCtD
Afatinib—ERBB2—embryo—ovarian cancer	0.00148	0.0247	CbGeAlD
Afatinib—ERBB4—embryo—ovarian cancer	0.00148	0.0247	CbGeAlD
Afatinib—HIPK4—gonad—ovarian cancer	0.00147	0.0244	CbGeAlD
Afatinib—HIPK4—female reproductive system—ovarian cancer	0.00131	0.0218	CbGeAlD
Afatinib—Gefitinib—CHEK2—ovarian cancer	0.00128	0.41	CrCbGaD
Afatinib—ERBB4—epithelium—ovarian cancer	0.00121	0.0201	CbGeAlD
Afatinib—ERBB2—epithelium—ovarian cancer	0.00121	0.0201	CbGeAlD
Afatinib—EPHA6—gonad—ovarian cancer	0.00116	0.0193	CbGeAlD
Afatinib—ERBB2—decidua—ovarian cancer	0.00114	0.019	CbGeAlD
Afatinib—PHKG2—gonad—ovarian cancer	0.00112	0.0186	CbGeAlD
Afatinib—DYRK1A—decidua—ovarian cancer	0.0011	0.0183	CbGeAlD
Afatinib—ERBB2—endometrium—ovarian cancer	0.00108	0.018	CbGeAlD
Afatinib—HIPK4—testis—ovarian cancer	0.00106	0.0176	CbGeAlD
Afatinib—EPHA6—female reproductive system—ovarian cancer	0.00104	0.0172	CbGeAlD
Afatinib—EGFR—uterine cervix—ovarian cancer	0.00102	0.0169	CbGeAlD
Afatinib—ERBB2—gonad—ovarian cancer	0.00101	0.0167	CbGeAlD
Afatinib—ERBB2—uterus—ovarian cancer	0.000999	0.0166	CbGeAlD
Afatinib—PHKG2—female reproductive system—ovarian cancer	0.000998	0.0166	CbGeAlD
Afatinib—DYRK1A—gonad—ovarian cancer	0.000968	0.0161	CbGeAlD
Afatinib—PHKG2—female gonad—ovarian cancer	0.000908	0.0151	CbGeAlD
Afatinib—ERBB2—female reproductive system—ovarian cancer	0.000898	0.0149	CbGeAlD
Afatinib—ERBB4—female reproductive system—ovarian cancer	0.000898	0.0149	CbGeAlD
Afatinib—IRAK1—uterine cervix—ovarian cancer	0.000896	0.0149	CbGeAlD
Afatinib—LCK—uterine cervix—ovarian cancer	0.000874	0.0146	CbGeAlD
Afatinib—DYRK1A—female reproductive system—ovarian cancer	0.000864	0.0144	CbGeAlD
Afatinib—IRAK1—decidua—ovarian cancer	0.000854	0.0142	CbGeAlD
Afatinib—EGFR—uterus—ovarian cancer	0.000847	0.0141	CbGeAlD
Afatinib—EPHA6—testis—ovarian cancer	0.000836	0.0139	CbGeAlD
Afatinib—LCK—decidua—ovarian cancer	0.000833	0.0139	CbGeAlD
Afatinib—ERBB2—female gonad—ovarian cancer	0.000817	0.0136	CbGeAlD
Afatinib—ERBB4—vagina—ovarian cancer	0.000812	0.0135	CbGeAlD
Afatinib—PHKG2—testis—ovarian cancer	0.000806	0.0134	CbGeAlD
Afatinib—DYRK1A—female gonad—ovarian cancer	0.000786	0.0131	CbGeAlD
Afatinib—BLK—lymph node—ovarian cancer	0.000766	0.0128	CbGeAlD
Afatinib—LCK—uterus—ovarian cancer	0.000728	0.0121	CbGeAlD
Afatinib—ERBB2—testis—ovarian cancer	0.000724	0.0121	CbGeAlD
Afatinib—ERBB4—testis—ovarian cancer	0.000724	0.0121	CbGeAlD
Afatinib—DYRK1A—testis—ovarian cancer	0.000697	0.0116	CbGeAlD
Afatinib—EGFR—female gonad—ovarian cancer	0.000692	0.0115	CbGeAlD
Afatinib—IRAK1—female reproductive system—ovarian cancer	0.000671	0.0112	CbGeAlD
Afatinib—ABL1—myometrium—ovarian cancer	0.000645	0.0107	CbGeAlD
Afatinib—Vandetanib—VEGFA—ovarian cancer	0.000638	0.204	CrCbGaD
Afatinib—IRAK1—bone marrow—ovarian cancer	0.000634	0.0106	CbGeAlD
Afatinib—ABL1—embryo—ovarian cancer	0.00062	0.0103	CbGeAlD
Afatinib—LCK—bone marrow—ovarian cancer	0.000618	0.0103	CbGeAlD
Afatinib—EGFR—testis—ovarian cancer	0.000614	0.0102	CbGeAlD
Afatinib—IRAK1—female gonad—ovarian cancer	0.000611	0.0102	CbGeAlD
Afatinib—LCK—female gonad—ovarian cancer	0.000596	0.00992	CbGeAlD
Afatinib—LCK—vagina—ovarian cancer	0.000592	0.00986	CbGeAlD
Afatinib—PHKG2—lymph node—ovarian cancer	0.000584	0.00973	CbGeAlD
Afatinib—IRAK1—testis—ovarian cancer	0.000542	0.00902	CbGeAlD
Afatinib—Vandetanib—EGFR—ovarian cancer	0.000538	0.172	CrCbGaD
Afatinib—LCK—testis—ovarian cancer	0.000529	0.0088	CbGeAlD
Afatinib—ERBB2—lymph node—ovarian cancer	0.000525	0.00875	CbGeAlD
Afatinib—Gefitinib—EGFR—ovarian cancer	0.000512	0.164	CrCbGaD
Afatinib—DYRK1A—lymph node—ovarian cancer	0.000505	0.00842	CbGeAlD
Afatinib—ABL1—uterine cervix—ovarian cancer	0.000502	0.00836	CbGeAlD
Afatinib—ABL1—decidua—ovarian cancer	0.000478	0.00797	CbGeAlD
Afatinib—ABL1—endometrium—ovarian cancer	0.000454	0.00756	CbGeAlD
Afatinib—EGFR—lymph node—ovarian cancer	0.000445	0.00741	CbGeAlD
Afatinib—ABL1—gonad—ovarian cancer	0.000421	0.00701	CbGeAlD
Afatinib—ABL1—uterus—ovarian cancer	0.000418	0.00697	CbGeAlD
Afatinib—ABCG2—myometrium—ovarian cancer	0.000407	0.00677	CbGeAlD
Afatinib—IRAK1—lymph node—ovarian cancer	0.000393	0.00654	CbGeAlD
Afatinib—LCK—lymph node—ovarian cancer	0.000383	0.00638	CbGeAlD
Afatinib—ABL1—female reproductive system—ovarian cancer	0.000376	0.00626	CbGeAlD
Afatinib—ABL1—bone marrow—ovarian cancer	0.000355	0.00591	CbGeAlD
Afatinib—ABL1—female gonad—ovarian cancer	0.000342	0.0057	CbGeAlD
Afatinib—ABL1—vagina—ovarian cancer	0.00034	0.00567	CbGeAlD
Afatinib—ABCG2—uterine cervix—ovarian cancer	0.000317	0.00527	CbGeAlD
Afatinib—ABL1—testis—ovarian cancer	0.000304	0.00506	CbGeAlD
Afatinib—ABCG2—decidua—ovarian cancer	0.000302	0.00502	CbGeAlD
Afatinib—ABCG2—endometrium—ovarian cancer	0.000286	0.00477	CbGeAlD
Afatinib—DYRK1A—Daunorubicin—Epirubicin—ovarian cancer	0.000276	0.0946	CbGdCrCtD
Afatinib—DYRK1A—Doxorubicin—Epirubicin—ovarian cancer	0.000276	0.0946	CbGdCrCtD
Afatinib—DYRK1A—Idarubicin—Epirubicin—ovarian cancer	0.000276	0.0946	CbGdCrCtD
Afatinib—ABCG2—uterus—ovarian cancer	0.000264	0.00439	CbGeAlD
Afatinib—DYRK1A—Idarubicin—Doxorubicin—ovarian cancer	0.000255	0.0875	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Doxorubicin—ovarian cancer	0.000255	0.0875	CbGdCrCtD
Afatinib—DYRK1A—Epirubicin—Doxorubicin—ovarian cancer	0.000255	0.0875	CbGdCrCtD
Afatinib—ABCG2—bone marrow—ovarian cancer	0.000224	0.00373	CbGeAlD
Afatinib—ABL1—lymph node—ovarian cancer	0.00022	0.00366	CbGeAlD
Afatinib—ABCG2—female gonad—ovarian cancer	0.000216	0.00359	CbGeAlD
Afatinib—ABCG2—vagina—ovarian cancer	0.000215	0.00357	CbGeAlD
Afatinib—ERBB2—Doxorubicin—Epirubicin—ovarian cancer	0.000212	0.0728	CbGdCrCtD
Afatinib—ABCB1—myometrium—ovarian cancer	0.000201	0.00334	CbGeAlD
Afatinib—ERBB2—Epirubicin—Doxorubicin—ovarian cancer	0.000196	0.0673	CbGdCrCtD
Afatinib—ABCB1—embryo—ovarian cancer	0.000193	0.00321	CbGeAlD
Afatinib—ABCG2—testis—ovarian cancer	0.000191	0.00319	CbGeAlD
Afatinib—Aspartate aminotransferase increased—Docetaxel—ovarian cancer	0.000181	0.00236	CcSEcCtD
Afatinib—Dyspnoea—Topotecan—ovarian cancer	0.000181	0.00236	CcSEcCtD
Afatinib—Cystitis—Epirubicin—ovarian cancer	0.00018	0.00236	CcSEcCtD
Afatinib—Body temperature increased—Chlorambucil—ovarian cancer	0.00018	0.00235	CcSEcCtD
Afatinib—Nasopharyngitis—Docetaxel—ovarian cancer	0.00018	0.00235	CcSEcCtD
Afatinib—Renal failure—Paclitaxel—ovarian cancer	0.00018	0.00235	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.000179	0.00235	CcSEcCtD
Afatinib—Dyspepsia—Topotecan—ovarian cancer	0.000178	0.00233	CcSEcCtD
Afatinib—Stomatitis—Paclitaxel—ovarian cancer	0.000178	0.00233	CcSEcCtD
Afatinib—Conjunctivitis—Paclitaxel—ovarian cancer	0.000178	0.00232	CcSEcCtD
Afatinib—Urinary tract infection—Paclitaxel—ovarian cancer	0.000178	0.00232	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Docetaxel—ovarian cancer	0.000177	0.00232	CcSEcCtD
Afatinib—Dyspnoea—Melphalan—ovarian cancer	0.000177	0.00231	CcSEcCtD
Afatinib—Decreased appetite—Topotecan—ovarian cancer	0.000176	0.0023	CcSEcCtD
Afatinib—Gastrointestinal disorder—Topotecan—ovarian cancer	0.000175	0.00229	CcSEcCtD
Afatinib—Fatigue—Topotecan—ovarian cancer	0.000175	0.00228	CcSEcCtD
Afatinib—Dyspepsia—Melphalan—ovarian cancer	0.000175	0.00228	CcSEcCtD
Afatinib—Constipation—Topotecan—ovarian cancer	0.000173	0.00226	CcSEcCtD
Afatinib—Hepatobiliary disease—Paclitaxel—ovarian cancer	0.000173	0.00226	CcSEcCtD
Afatinib—Dry eye—Epirubicin—ovarian cancer	0.000172	0.00225	CcSEcCtD
Afatinib—Decreased appetite—Melphalan—ovarian cancer	0.000172	0.00225	CcSEcCtD
Afatinib—Epistaxis—Paclitaxel—ovarian cancer	0.000172	0.00225	CcSEcCtD
Afatinib—Infection—Vinorelbine—ovarian cancer	0.000172	0.00225	CcSEcCtD
Afatinib—Gastrointestinal disorder—Melphalan—ovarian cancer	0.000171	0.00224	CcSEcCtD
Afatinib—Fatigue—Melphalan—ovarian cancer	0.000171	0.00223	CcSEcCtD
Afatinib—Nervous system disorder—Vinorelbine—ovarian cancer	0.00017	0.00222	CcSEcCtD
Afatinib—Bladder pain—Epirubicin—ovarian cancer	0.000169	0.00221	CcSEcCtD
Afatinib—Mouth ulceration—Epirubicin—ovarian cancer	0.000169	0.00221	CcSEcCtD
Afatinib—Cystitis noninfective—Doxorubicin—ovarian cancer	0.000169	0.00221	CcSEcCtD
Afatinib—Skin disorder—Vinorelbine—ovarian cancer	0.000168	0.0022	CcSEcCtD
Afatinib—Cystitis—Doxorubicin—ovarian cancer	0.000167	0.00218	CcSEcCtD
Afatinib—Asthenia—Chlorambucil—ovarian cancer	0.000163	0.00213	CcSEcCtD
Afatinib—Sepsis—Epirubicin—ovarian cancer	0.000162	0.00212	CcSEcCtD
Afatinib—Urinary tract disorder—Paclitaxel—ovarian cancer	0.000162	0.00212	CcSEcCtD
Afatinib—Connective tissue disorder—Paclitaxel—ovarian cancer	0.000161	0.00211	CcSEcCtD
Afatinib—Pruritus—Chlorambucil—ovarian cancer	0.000161	0.0021	CcSEcCtD
Afatinib—Urethral disorder—Paclitaxel—ovarian cancer	0.000161	0.0021	CcSEcCtD
Afatinib—Body temperature increased—Topotecan—ovarian cancer	0.00016	0.00209	CcSEcCtD
Afatinib—Dry eye—Doxorubicin—ovarian cancer	0.00016	0.00209	CcSEcCtD
Afatinib—ABL1—Daunorubicin—Epirubicin—ovarian cancer	0.000158	0.0543	CbGdCrCtD
Afatinib—ABL1—Idarubicin—Epirubicin—ovarian cancer	0.000158	0.0543	CbGdCrCtD
Afatinib—ABL1—Doxorubicin—Epirubicin—ovarian cancer	0.000158	0.0543	CbGdCrCtD
Afatinib—ABCB1—epithelium—ovarian cancer	0.000157	0.00262	CbGeAlD
Afatinib—Weight decreased—Docetaxel—ovarian cancer	0.000157	0.00205	CcSEcCtD
Afatinib—Mouth ulceration—Doxorubicin—ovarian cancer	0.000156	0.00204	CcSEcCtD
Afatinib—Bladder pain—Doxorubicin—ovarian cancer	0.000156	0.00204	CcSEcCtD
Afatinib—ABCB1—uterine cervix—ovarian cancer	0.000156	0.0026	CbGeAlD
Afatinib—Pneumonia—Docetaxel—ovarian cancer	0.000156	0.00204	CcSEcCtD
Afatinib—Diarrhoea—Chlorambucil—ovarian cancer	0.000156	0.00203	CcSEcCtD
Afatinib—Gefitinib—ABCB1—ovarian cancer	0.000156	0.0498	CrCbGaD
Afatinib—Infestation NOS—Docetaxel—ovarian cancer	0.000155	0.00202	CcSEcCtD
Afatinib—Infestation—Docetaxel—ovarian cancer	0.000155	0.00202	CcSEcCtD
Afatinib—Dyspnoea—Vinorelbine—ovarian cancer	0.000154	0.00202	CcSEcCtD
Afatinib—Eye disorder—Paclitaxel—ovarian cancer	0.000153	0.002	CcSEcCtD
Afatinib—Renal failure—Docetaxel—ovarian cancer	0.000152	0.00199	CcSEcCtD
Afatinib—Stomatitis—Docetaxel—ovarian cancer	0.000151	0.00197	CcSEcCtD
Afatinib—Decreased appetite—Vinorelbine—ovarian cancer	0.000151	0.00197	CcSEcCtD
Afatinib—Conjunctivitis—Docetaxel—ovarian cancer	0.000151	0.00197	CcSEcCtD
Afatinib—Sepsis—Doxorubicin—ovarian cancer	0.00015	0.00196	CcSEcCtD
Afatinib—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.00015	0.00195	CcSEcCtD
Afatinib—Fatigue—Vinorelbine—ovarian cancer	0.000149	0.00195	CcSEcCtD
Afatinib—ABCB1—decidua—ovarian cancer	0.000149	0.00248	CbGeAlD
Afatinib—Constipation—Vinorelbine—ovarian cancer	0.000148	0.00194	CcSEcCtD
Afatinib—Mediastinal disorder—Paclitaxel—ovarian cancer	0.000148	0.00193	CcSEcCtD
Afatinib—Hepatobiliary disease—Docetaxel—ovarian cancer	0.000146	0.00191	CcSEcCtD
Afatinib—ABL1—Idarubicin—Doxorubicin—ovarian cancer	0.000146	0.0503	CbGdCrCtD
Afatinib—ABL1—Daunorubicin—Doxorubicin—ovarian cancer	0.000146	0.0503	CbGdCrCtD
Afatinib—ABL1—Epirubicin—Doxorubicin—ovarian cancer	0.000146	0.0503	CbGdCrCtD
Afatinib—Epistaxis—Docetaxel—ovarian cancer	0.000146	0.00191	CcSEcCtD
Afatinib—Asthenia—Topotecan—ovarian cancer	0.000145	0.0019	CcSEcCtD
Afatinib—Alopecia—Paclitaxel—ovarian cancer	0.000145	0.00189	CcSEcCtD
Afatinib—Vomiting—Chlorambucil—ovarian cancer	0.000145	0.00189	CcSEcCtD
Afatinib—Mental disorder—Paclitaxel—ovarian cancer	0.000144	0.00188	CcSEcCtD
Afatinib—Pruritus—Topotecan—ovarian cancer	0.000143	0.00187	CcSEcCtD
Afatinib—Malnutrition—Paclitaxel—ovarian cancer	0.000143	0.00187	CcSEcCtD
Afatinib—Renal impairment—Epirubicin—ovarian cancer	0.000142	0.00186	CcSEcCtD
Afatinib—Asthenia—Melphalan—ovarian cancer	0.000142	0.00186	CcSEcCtD
Afatinib—ABCB1—endometrium—ovarian cancer	0.000141	0.00235	CbGeAlD
Afatinib—Pruritus—Melphalan—ovarian cancer	0.00014	0.00183	CcSEcCtD
Afatinib—Dysgeusia—Paclitaxel—ovarian cancer	0.00014	0.00183	CcSEcCtD
Afatinib—ABCG2—lymph node—ovarian cancer	0.000139	0.00231	CbGeAlD
Afatinib—Diarrhoea—Topotecan—ovarian cancer	0.000139	0.00181	CcSEcCtD
Afatinib—Back pain—Paclitaxel—ovarian cancer	0.000138	0.0018	CcSEcCtD
Afatinib—Urinary tract disorder—Docetaxel—ovarian cancer	0.000137	0.00179	CcSEcCtD
Afatinib—Muscle spasms—Paclitaxel—ovarian cancer	0.000137	0.00179	CcSEcCtD
Afatinib—Body temperature increased—Vinorelbine—ovarian cancer	0.000137	0.00179	CcSEcCtD
Afatinib—Connective tissue disorder—Docetaxel—ovarian cancer	0.000137	0.00179	CcSEcCtD
Afatinib—Urethral disorder—Docetaxel—ovarian cancer	0.000136	0.00178	CcSEcCtD
Afatinib—Diarrhoea—Melphalan—ovarian cancer	0.000136	0.00177	CcSEcCtD
Afatinib—Nausea—Chlorambucil—ovarian cancer	0.000135	0.00177	CcSEcCtD
Afatinib—Dizziness—Topotecan—ovarian cancer	0.000134	0.00175	CcSEcCtD
Afatinib—Renal impairment—Doxorubicin—ovarian cancer	0.000132	0.00172	CcSEcCtD
Afatinib—ABCB1—gonad—ovarian cancer	0.000131	0.00218	CbGeAlD
Afatinib—ABCB1—uterus—ovarian cancer	0.00013	0.00217	CbGeAlD
Afatinib—Eye disorder—Docetaxel—ovarian cancer	0.00013	0.0017	CcSEcCtD
Afatinib—Vomiting—Topotecan—ovarian cancer	0.000129	0.00168	CcSEcCtD
Afatinib—Rash—Topotecan—ovarian cancer	0.000128	0.00167	CcSEcCtD
Afatinib—Dermatitis—Topotecan—ovarian cancer	0.000128	0.00167	CcSEcCtD
Afatinib—Headache—Topotecan—ovarian cancer	0.000127	0.00166	CcSEcCtD
Afatinib—Vomiting—Melphalan—ovarian cancer	0.000126	0.00165	CcSEcCtD
Afatinib—Dehydration—Epirubicin—ovarian cancer	0.000126	0.00165	CcSEcCtD
Afatinib—Mediastinal disorder—Docetaxel—ovarian cancer	0.000125	0.00164	CcSEcCtD
Afatinib—Rash—Melphalan—ovarian cancer	0.000125	0.00163	CcSEcCtD
Afatinib—Dermatitis—Melphalan—ovarian cancer	0.000125	0.00163	CcSEcCtD
Afatinib—Cough—Paclitaxel—ovarian cancer	0.000125	0.00163	CcSEcCtD
Afatinib—Asthenia—Vinorelbine—ovarian cancer	0.000124	0.00162	CcSEcCtD
Afatinib—Dry skin—Epirubicin—ovarian cancer	0.000124	0.00162	CcSEcCtD
Afatinib—Hypokalaemia—Epirubicin—ovarian cancer	0.000123	0.00161	CcSEcCtD
Afatinib—Alopecia—Docetaxel—ovarian cancer	0.000123	0.00161	CcSEcCtD
Afatinib—Pruritus—Vinorelbine—ovarian cancer	0.000123	0.0016	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.000122	0.0016	CcSEcCtD
Afatinib—Mental disorder—Docetaxel—ovarian cancer	0.000122	0.00159	CcSEcCtD
Afatinib—Nasopharyngitis—Epirubicin—ovarian cancer	0.000121	0.00158	CcSEcCtD
Afatinib—Malnutrition—Docetaxel—ovarian cancer	0.000121	0.00158	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000121	0.00158	CcSEcCtD
Afatinib—Nausea—Topotecan—ovarian cancer	0.00012	0.00157	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.00012	0.00156	CcSEcCtD
Afatinib—Diarrhoea—Vinorelbine—ovarian cancer	0.000119	0.00155	CcSEcCtD
Afatinib—Dysgeusia—Docetaxel—ovarian cancer	0.000118	0.00155	CcSEcCtD
Afatinib—Nausea—Melphalan—ovarian cancer	0.000118	0.00154	CcSEcCtD
Afatinib—Back pain—Docetaxel—ovarian cancer	0.000117	0.00153	CcSEcCtD
Afatinib—ABCB1—female reproductive system—ovarian cancer	0.000117	0.00195	CbGeAlD
Afatinib—Dehydration—Doxorubicin—ovarian cancer	0.000117	0.00152	CcSEcCtD
Afatinib—Muscle spasms—Docetaxel—ovarian cancer	0.000116	0.00152	CcSEcCtD
Afatinib—Infection—Paclitaxel—ovarian cancer	0.000116	0.00151	CcSEcCtD
Afatinib—Dry skin—Doxorubicin—ovarian cancer	0.000115	0.0015	CcSEcCtD
Afatinib—Dizziness—Vinorelbine—ovarian cancer	0.000115	0.0015	CcSEcCtD
Afatinib—Nervous system disorder—Paclitaxel—ovarian cancer	0.000114	0.00149	CcSEcCtD
Afatinib—Hypokalaemia—Doxorubicin—ovarian cancer	0.000114	0.00149	CcSEcCtD
Afatinib—Skin disorder—Paclitaxel—ovarian cancer	0.000113	0.00148	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000113	0.00148	CcSEcCtD
Afatinib—Nasopharyngitis—Doxorubicin—ovarian cancer	0.000112	0.00147	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000111	0.00145	CcSEcCtD
Afatinib—ABCB1—bone marrow—ovarian cancer	0.00011	0.00184	CbGeAlD
Afatinib—Vomiting—Vinorelbine—ovarian cancer	0.00011	0.00144	CcSEcCtD
Afatinib—Rash—Vinorelbine—ovarian cancer	0.000109	0.00143	CcSEcCtD
Afatinib—Dermatitis—Vinorelbine—ovarian cancer	0.000109	0.00143	CcSEcCtD
Afatinib—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000109	0.00142	CcSEcCtD
Afatinib—Headache—Vinorelbine—ovarian cancer	0.000109	0.00142	CcSEcCtD
Afatinib—ABCB1—female gonad—ovarian cancer	0.000106	0.00177	CbGeAlD
Afatinib—Weight decreased—Epirubicin—ovarian cancer	0.000106	0.00139	CcSEcCtD
Afatinib—ABCB1—vagina—ovarian cancer	0.000106	0.00176	CbGeAlD
Afatinib—Cough—Docetaxel—ovarian cancer	0.000106	0.00138	CcSEcCtD
Afatinib—Insomnia—Paclitaxel—ovarian cancer	0.000105	0.00138	CcSEcCtD
Afatinib—Pneumonia—Epirubicin—ovarian cancer	0.000105	0.00137	CcSEcCtD
Afatinib—Infestation NOS—Epirubicin—ovarian cancer	0.000104	0.00137	CcSEcCtD
Afatinib—Infestation—Epirubicin—ovarian cancer	0.000104	0.00137	CcSEcCtD
Afatinib—Dyspnoea—Paclitaxel—ovarian cancer	0.000104	0.00136	CcSEcCtD
Afatinib—Nausea—Vinorelbine—ovarian cancer	0.000103	0.00134	CcSEcCtD
Afatinib—Renal failure—Epirubicin—ovarian cancer	0.000103	0.00134	CcSEcCtD
Afatinib—Dyspepsia—Paclitaxel—ovarian cancer	0.000103	0.00134	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000102	0.00134	CcSEcCtD
Afatinib—Stomatitis—Epirubicin—ovarian cancer	0.000102	0.00133	CcSEcCtD
Afatinib—Conjunctivitis—Epirubicin—ovarian cancer	0.000102	0.00133	CcSEcCtD
Afatinib—Urinary tract infection—Epirubicin—ovarian cancer	0.000102	0.00133	CcSEcCtD
Afatinib—Decreased appetite—Paclitaxel—ovarian cancer	0.000101	0.00132	CcSEcCtD
Afatinib—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000101	0.00132	CcSEcCtD
Afatinib—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000101	0.00131	CcSEcCtD
Afatinib—Fatigue—Paclitaxel—ovarian cancer	0.0001	0.00131	CcSEcCtD
Afatinib—Constipation—Paclitaxel—ovarian cancer	9.96e-05	0.0013	CcSEcCtD
Afatinib—Hepatobiliary disease—Epirubicin—ovarian cancer	9.88e-05	0.00129	CcSEcCtD
Afatinib—Epistaxis—Epirubicin—ovarian cancer	9.85e-05	0.00129	CcSEcCtD
Afatinib—Infection—Docetaxel—ovarian cancer	9.81e-05	0.00128	CcSEcCtD
Afatinib—Weight decreased—Doxorubicin—ovarian cancer	9.81e-05	0.00128	CcSEcCtD
Afatinib—Pneumonia—Doxorubicin—ovarian cancer	9.72e-05	0.00127	CcSEcCtD
Afatinib—Nervous system disorder—Docetaxel—ovarian cancer	9.68e-05	0.00127	CcSEcCtD
Afatinib—Infestation NOS—Doxorubicin—ovarian cancer	9.66e-05	0.00126	CcSEcCtD
Afatinib—Infestation—Doxorubicin—ovarian cancer	9.66e-05	0.00126	CcSEcCtD
Afatinib—Skin disorder—Docetaxel—ovarian cancer	9.59e-05	0.00125	CcSEcCtD
Afatinib—Renal failure—Doxorubicin—ovarian cancer	9.5e-05	0.00124	CcSEcCtD
Afatinib—ABCB1—testis—ovarian cancer	9.44e-05	0.00157	CbGeAlD
Afatinib—Stomatitis—Doxorubicin—ovarian cancer	9.42e-05	0.00123	CcSEcCtD
Afatinib—Conjunctivitis—Doxorubicin—ovarian cancer	9.39e-05	0.00123	CcSEcCtD
Afatinib—Urinary tract infection—Doxorubicin—ovarian cancer	9.39e-05	0.00123	CcSEcCtD
Afatinib—Urinary tract disorder—Epirubicin—ovarian cancer	9.26e-05	0.00121	CcSEcCtD
Afatinib—Connective tissue disorder—Epirubicin—ovarian cancer	9.21e-05	0.0012	CcSEcCtD
Afatinib—Body temperature increased—Paclitaxel—ovarian cancer	9.21e-05	0.0012	CcSEcCtD
Afatinib—Urethral disorder—Epirubicin—ovarian cancer	9.19e-05	0.0012	CcSEcCtD
Afatinib—Hepatobiliary disease—Doxorubicin—ovarian cancer	9.14e-05	0.00119	CcSEcCtD
Afatinib—Epistaxis—Doxorubicin—ovarian cancer	9.11e-05	0.00119	CcSEcCtD
Afatinib—Insomnia—Docetaxel—ovarian cancer	8.93e-05	0.00117	CcSEcCtD
Afatinib—Dyspnoea—Docetaxel—ovarian cancer	8.8e-05	0.00115	CcSEcCtD
Afatinib—Eye disorder—Epirubicin—ovarian cancer	8.76e-05	0.00115	CcSEcCtD
Afatinib—Dyspepsia—Docetaxel—ovarian cancer	8.69e-05	0.00114	CcSEcCtD
Afatinib—Decreased appetite—Docetaxel—ovarian cancer	8.58e-05	0.00112	CcSEcCtD
Afatinib—Urinary tract disorder—Doxorubicin—ovarian cancer	8.57e-05	0.00112	CcSEcCtD
Afatinib—Gastrointestinal disorder—Docetaxel—ovarian cancer	8.53e-05	0.00111	CcSEcCtD
Afatinib—Connective tissue disorder—Doxorubicin—ovarian cancer	8.52e-05	0.00111	CcSEcCtD
Afatinib—Fatigue—Docetaxel—ovarian cancer	8.51e-05	0.00111	CcSEcCtD
Afatinib—Urethral disorder—Doxorubicin—ovarian cancer	8.5e-05	0.00111	CcSEcCtD
Afatinib—Mediastinal disorder—Epirubicin—ovarian cancer	8.45e-05	0.0011	CcSEcCtD
Afatinib—Constipation—Docetaxel—ovarian cancer	8.44e-05	0.0011	CcSEcCtD
Afatinib—Asthenia—Paclitaxel—ovarian cancer	8.36e-05	0.00109	CcSEcCtD
Afatinib—Alopecia—Epirubicin—ovarian cancer	8.28e-05	0.00108	CcSEcCtD
Afatinib—Pruritus—Paclitaxel—ovarian cancer	8.24e-05	0.00108	CcSEcCtD
Afatinib—Mental disorder—Epirubicin—ovarian cancer	8.21e-05	0.00107	CcSEcCtD
Afatinib—Malnutrition—Epirubicin—ovarian cancer	8.16e-05	0.00107	CcSEcCtD
Afatinib—Eye disorder—Doxorubicin—ovarian cancer	8.11e-05	0.00106	CcSEcCtD
Afatinib—Dysgeusia—Epirubicin—ovarian cancer	7.99e-05	0.00104	CcSEcCtD
Afatinib—Diarrhoea—Paclitaxel—ovarian cancer	7.97e-05	0.00104	CcSEcCtD
Afatinib—Back pain—Epirubicin—ovarian cancer	7.89e-05	0.00103	CcSEcCtD
Afatinib—Muscle spasms—Epirubicin—ovarian cancer	7.85e-05	0.00103	CcSEcCtD
Afatinib—Mediastinal disorder—Doxorubicin—ovarian cancer	7.82e-05	0.00102	CcSEcCtD
Afatinib—Body temperature increased—Docetaxel—ovarian cancer	7.81e-05	0.00102	CcSEcCtD
Afatinib—Dizziness—Paclitaxel—ovarian cancer	7.7e-05	0.00101	CcSEcCtD
Afatinib—Alopecia—Doxorubicin—ovarian cancer	7.67e-05	0.001	CcSEcCtD
Afatinib—Mental disorder—Doxorubicin—ovarian cancer	7.6e-05	0.000993	CcSEcCtD
Afatinib—Malnutrition—Doxorubicin—ovarian cancer	7.55e-05	0.000987	CcSEcCtD
Afatinib—Vomiting—Paclitaxel—ovarian cancer	7.41e-05	0.000968	CcSEcCtD
Afatinib—Dysgeusia—Doxorubicin—ovarian cancer	7.4e-05	0.000967	CcSEcCtD
Afatinib—Rash—Paclitaxel—ovarian cancer	7.35e-05	0.00096	CcSEcCtD
Afatinib—Dermatitis—Paclitaxel—ovarian cancer	7.34e-05	0.000959	CcSEcCtD
Afatinib—Back pain—Doxorubicin—ovarian cancer	7.3e-05	0.000955	CcSEcCtD
Afatinib—Headache—Paclitaxel—ovarian cancer	7.3e-05	0.000954	CcSEcCtD
Afatinib—Muscle spasms—Doxorubicin—ovarian cancer	7.26e-05	0.000949	CcSEcCtD
Afatinib—Cough—Epirubicin—ovarian cancer	7.12e-05	0.000931	CcSEcCtD
Afatinib—Asthenia—Docetaxel—ovarian cancer	7.09e-05	0.000926	CcSEcCtD
Afatinib—Pruritus—Docetaxel—ovarian cancer	6.99e-05	0.000913	CcSEcCtD
Afatinib—Nausea—Paclitaxel—ovarian cancer	6.92e-05	0.000905	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	6.9e-05	0.000902	CcSEcCtD
Afatinib—ABCB1—lymph node—ovarian cancer	6.84e-05	0.00114	CbGeAlD
Afatinib—Diarrhoea—Docetaxel—ovarian cancer	6.76e-05	0.000883	CcSEcCtD
Afatinib—Infection—Epirubicin—ovarian cancer	6.62e-05	0.000865	CcSEcCtD
Afatinib—Cough—Doxorubicin—ovarian cancer	6.59e-05	0.000861	CcSEcCtD
Afatinib—Nervous system disorder—Epirubicin—ovarian cancer	6.53e-05	0.000854	CcSEcCtD
Afatinib—Dizziness—Docetaxel—ovarian cancer	6.53e-05	0.000854	CcSEcCtD
Afatinib—Skin disorder—Epirubicin—ovarian cancer	6.47e-05	0.000846	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	6.38e-05	0.000835	CcSEcCtD
Afatinib—Vomiting—Docetaxel—ovarian cancer	6.28e-05	0.000821	CcSEcCtD
Afatinib—Rash—Docetaxel—ovarian cancer	6.23e-05	0.000814	CcSEcCtD
Afatinib—Dermatitis—Docetaxel—ovarian cancer	6.22e-05	0.000813	CcSEcCtD
Afatinib—Headache—Docetaxel—ovarian cancer	6.19e-05	0.000809	CcSEcCtD
Afatinib—Infection—Doxorubicin—ovarian cancer	6.12e-05	0.0008	CcSEcCtD
Afatinib—Nervous system disorder—Doxorubicin—ovarian cancer	6.04e-05	0.00079	CcSEcCtD
Afatinib—Insomnia—Epirubicin—ovarian cancer	6.02e-05	0.000787	CcSEcCtD
Afatinib—Skin disorder—Doxorubicin—ovarian cancer	5.99e-05	0.000782	CcSEcCtD
Afatinib—Dyspnoea—Epirubicin—ovarian cancer	5.94e-05	0.000776	CcSEcCtD
Afatinib—Nausea—Docetaxel—ovarian cancer	5.87e-05	0.000767	CcSEcCtD
Afatinib—Dyspepsia—Epirubicin—ovarian cancer	5.86e-05	0.000766	CcSEcCtD
Afatinib—Decreased appetite—Epirubicin—ovarian cancer	5.79e-05	0.000757	CcSEcCtD
Afatinib—Gastrointestinal disorder—Epirubicin—ovarian cancer	5.75e-05	0.000752	CcSEcCtD
Afatinib—Fatigue—Epirubicin—ovarian cancer	5.74e-05	0.000751	CcSEcCtD
Afatinib—Constipation—Epirubicin—ovarian cancer	5.7e-05	0.000745	CcSEcCtD
Afatinib—Insomnia—Doxorubicin—ovarian cancer	5.57e-05	0.000729	CcSEcCtD
Afatinib—Dyspnoea—Doxorubicin—ovarian cancer	5.49e-05	0.000718	CcSEcCtD
Afatinib—Dyspepsia—Doxorubicin—ovarian cancer	5.43e-05	0.000709	CcSEcCtD
Afatinib—Decreased appetite—Doxorubicin—ovarian cancer	5.36e-05	0.0007	CcSEcCtD
Afatinib—Gastrointestinal disorder—Doxorubicin—ovarian cancer	5.32e-05	0.000695	CcSEcCtD
Afatinib—Fatigue—Doxorubicin—ovarian cancer	5.31e-05	0.000695	CcSEcCtD
Afatinib—Constipation—Doxorubicin—ovarian cancer	5.27e-05	0.000689	CcSEcCtD
Afatinib—Body temperature increased—Epirubicin—ovarian cancer	5.27e-05	0.000688	CcSEcCtD
Afatinib—Body temperature increased—Doxorubicin—ovarian cancer	4.87e-05	0.000637	CcSEcCtD
Afatinib—Asthenia—Epirubicin—ovarian cancer	4.78e-05	0.000625	CcSEcCtD
Afatinib—Pruritus—Epirubicin—ovarian cancer	4.71e-05	0.000616	CcSEcCtD
Afatinib—Diarrhoea—Epirubicin—ovarian cancer	4.56e-05	0.000596	CcSEcCtD
Afatinib—Asthenia—Doxorubicin—ovarian cancer	4.42e-05	0.000578	CcSEcCtD
Afatinib—Dizziness—Epirubicin—ovarian cancer	4.4e-05	0.000576	CcSEcCtD
Afatinib—Pruritus—Doxorubicin—ovarian cancer	4.36e-05	0.00057	CcSEcCtD
Afatinib—Vomiting—Epirubicin—ovarian cancer	4.24e-05	0.000554	CcSEcCtD
Afatinib—Diarrhoea—Doxorubicin—ovarian cancer	4.22e-05	0.000551	CcSEcCtD
Afatinib—Rash—Epirubicin—ovarian cancer	4.2e-05	0.000549	CcSEcCtD
Afatinib—Dermatitis—Epirubicin—ovarian cancer	4.2e-05	0.000548	CcSEcCtD
Afatinib—Headache—Epirubicin—ovarian cancer	4.17e-05	0.000545	CcSEcCtD
Afatinib—Dizziness—Doxorubicin—ovarian cancer	4.08e-05	0.000533	CcSEcCtD
Afatinib—Nausea—Epirubicin—ovarian cancer	3.96e-05	0.000517	CcSEcCtD
Afatinib—Vomiting—Doxorubicin—ovarian cancer	3.92e-05	0.000512	CcSEcCtD
Afatinib—Rash—Doxorubicin—ovarian cancer	3.89e-05	0.000508	CcSEcCtD
Afatinib—Dermatitis—Doxorubicin—ovarian cancer	3.88e-05	0.000507	CcSEcCtD
Afatinib—Headache—Doxorubicin—ovarian cancer	3.86e-05	0.000505	CcSEcCtD
Afatinib—Nausea—Doxorubicin—ovarian cancer	3.66e-05	0.000479	CcSEcCtD
Afatinib—EGFR—Innate Immune System—PIK3CA—ovarian cancer	3.33e-06	2.72e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	3.33e-06	2.72e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—VEGFA—ovarian cancer	3.32e-06	2.72e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CTNNB1—ovarian cancer	3.3e-06	2.7e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—HRAS—ovarian cancer	3.3e-06	2.7e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CAV1—ovarian cancer	3.29e-06	2.69e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—STAT3—ovarian cancer	3.29e-06	2.69e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NRAS—ovarian cancer	3.28e-06	2.68e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—IL6—ovarian cancer	3.28e-06	2.68e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—AKT1—ovarian cancer	3.28e-06	2.68e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—VEGFA—ovarian cancer	3.27e-06	2.68e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CD—ovarian cancer	3.25e-06	2.66e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—STAT3—ovarian cancer	3.24e-06	2.65e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NRAS—ovarian cancer	3.23e-06	2.64e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—IL6—ovarian cancer	3.23e-06	2.64e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—AKT1—ovarian cancer	3.23e-06	2.64e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—ERBB2—ovarian cancer	3.23e-06	2.64e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—PTEN—ovarian cancer	3.22e-06	2.63e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—PIK3CA—ovarian cancer	3.21e-06	2.63e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL2—ovarian cancer	3.2e-06	2.62e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—PIK3CA—ovarian cancer	3.2e-06	2.62e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TERT—ovarian cancer	3.19e-06	2.61e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—AKT1—ovarian cancer	3.19e-06	2.6e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—MTOR—ovarian cancer	3.18e-06	2.6e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PIK3CB—ovarian cancer	3.18e-06	2.6e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—KRAS—ovarian cancer	3.16e-06	2.58e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MAPK3—ovarian cancer	3.14e-06	2.57e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—ERBB2—ovarian cancer	3.12e-06	2.55e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—ERBB2—ovarian cancer	3.11e-06	2.54e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—AKT1—ovarian cancer	3.11e-06	2.54e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MAPK3—ovarian cancer	3.1e-06	2.53e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—PIK3CA—ovarian cancer	3.08e-06	2.52e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—HRAS—ovarian cancer	3.08e-06	2.52e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—AKT1—ovarian cancer	3.08e-06	2.52e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MTOR—ovarian cancer	3.08e-06	2.52e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3CB—ovarian cancer	3.08e-06	2.52e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TERT—ovarian cancer	3.07e-06	2.51e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PIK3CB—ovarian cancer	3.07e-06	2.51e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—MTOR—ovarian cancer	3.07e-06	2.51e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MYC—ovarian cancer	3.06e-06	2.5e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—AKT1—ovarian cancer	3.03e-06	2.48e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MYC—ovarian cancer	3.01e-06	2.46e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CG—ovarian cancer	3e-06	2.45e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—FASN—ovarian cancer	3e-06	2.45e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MAPK1—ovarian cancer	2.99e-06	2.45e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—EGFR—ovarian cancer	2.99e-06	2.45e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CDKN1B—ovarian cancer	2.99e-06	2.44e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—AKT1—ovarian cancer	2.98e-06	2.44e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—ERBB2—ovarian cancer	2.98e-06	2.44e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—HRAS—ovarian cancer	2.97e-06	2.43e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HRAS—ovarian cancer	2.96e-06	2.42e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CXCL8—ovarian cancer	2.96e-06	2.42e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—IL6—ovarian cancer	2.95e-06	2.41e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—SLC5A5—ovarian cancer	2.95e-06	2.41e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CAV1—ovarian cancer	2.95e-06	2.41e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MAPK1—ovarian cancer	2.95e-06	2.41e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—EGFR—ovarian cancer	2.95e-06	2.41e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MTOR—ovarian cancer	2.94e-06	2.4e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CB—ovarian cancer	2.94e-06	2.4e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL2—ovarian cancer	2.92e-06	2.39e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—AKT1—ovarian cancer	2.91e-06	2.38e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—PIK3CA—ovarian cancer	2.9e-06	2.37e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CDKN1B—ovarian cancer	2.89e-06	2.36e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CDKN1B—ovarian cancer	2.88e-06	2.35e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—STAT3—ovarian cancer	2.88e-06	2.35e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—NRAS—ovarian cancer	2.87e-06	2.35e-05	CbGpPWpGaD
Afatinib—LCK—Disease—ERBB2—ovarian cancer	2.87e-06	2.35e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HRAS—ovarian cancer	2.85e-06	2.33e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—SLC2A1—ovarian cancer	2.85e-06	2.33e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—IL6—ovarian cancer	2.84e-06	2.33e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CAV1—ovarian cancer	2.84e-06	2.32e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ESR1—ovarian cancer	2.84e-06	2.32e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CB—ovarian cancer	2.83e-06	2.32e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MTOR—ovarian cancer	2.83e-06	2.32e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CASP3—ovarian cancer	2.83e-06	2.32e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL2—ovarian cancer	2.83e-06	2.31e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—KRAS—ovarian cancer	2.83e-06	2.31e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CTNNB1—ovarian cancer	2.82e-06	2.31e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL2—ovarian cancer	2.82e-06	2.3e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6ST—ovarian cancer	2.8e-06	2.29e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—KRAS—ovarian cancer	2.78e-06	2.28e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CDKN1B—ovarian cancer	2.76e-06	2.26e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCND1—ovarian cancer	2.76e-06	2.25e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PTEN—ovarian cancer	2.75e-06	2.25e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—MAPK3—ovarian cancer	2.75e-06	2.25e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ESR1—ovarian cancer	2.74e-06	2.24e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP1B1—ovarian cancer	2.73e-06	2.23e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CTNNB1—ovarian cancer	2.73e-06	2.23e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—AKT1—ovarian cancer	2.72e-06	2.23e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CTNNB1—ovarian cancer	2.72e-06	2.22e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6ST—ovarian cancer	2.7e-06	2.2e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APC—ovarian cancer	2.69e-06	2.2e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CG—ovarian cancer	2.69e-06	2.2e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—NRAS—ovarian cancer	2.69e-06	2.2e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HRAS—ovarian cancer	2.69e-06	2.2e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MMP9—ovarian cancer	2.68e-06	2.19e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PTEN—ovarian cancer	2.66e-06	2.17e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CDKN1B—ovarian cancer	2.66e-06	2.17e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PTEN—ovarian cancer	2.65e-06	2.17e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CD—ovarian cancer	2.64e-06	2.16e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—AKT1—ovarian cancer	2.62e-06	2.14e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—MAPK1—ovarian cancer	2.62e-06	2.14e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—EGFR—ovarian cancer	2.62e-06	2.14e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—AKT1—ovarian cancer	2.61e-06	2.14e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CTNNB1—ovarian cancer	2.61e-06	2.13e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PIK3CA—ovarian cancer	2.6e-06	2.12e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APC—ovarian cancer	2.59e-06	2.12e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CG—ovarian cancer	2.59e-06	2.12e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—MAPK3—ovarian cancer	2.57e-06	2.1e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL6—ovarian cancer	2.57e-06	2.1e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PIK3CA—ovarian cancer	2.56e-06	2.09e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTEN—ovarian cancer	2.54e-06	2.08e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—AKT1—ovarian cancer	2.52e-06	2.06e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CTNNB1—ovarian cancer	2.51e-06	2.05e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—ovarian cancer	2.51e-06	2.05e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—ovarian cancer	2.47e-06	2.02e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—KRAS—ovarian cancer	2.47e-06	2.02e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—STAT3—ovarian cancer	2.46e-06	2.01e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—NRAS—ovarian cancer	2.46e-06	2.01e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—MAPK1—ovarian cancer	2.45e-06	2e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTEN—ovarian cancer	2.45e-06	2e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PPP2R1A—ovarian cancer	2.42e-06	1.98e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—VEGFA—ovarian cancer	2.4e-06	1.96e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—HRAS—ovarian cancer	2.4e-06	1.96e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—STAT3—ovarian cancer	2.38e-06	1.95e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NRAS—ovarian cancer	2.37e-06	1.94e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—STAT3—ovarian cancer	2.37e-06	1.94e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—AKT1—ovarian cancer	2.37e-06	1.94e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—HRAS—ovarian cancer	2.37e-06	1.93e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—NRAS—ovarian cancer	2.37e-06	1.93e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CD—ovarian cancer	2.36e-06	1.93e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—MAPK3—ovarian cancer	2.35e-06	1.92e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—KRAS—ovarian cancer	2.31e-06	1.89e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL6—ovarian cancer	2.3e-06	1.88e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CB—ovarian cancer	2.3e-06	1.88e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CD—ovarian cancer	2.28e-06	1.86e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MAPK3—ovarian cancer	2.27e-06	1.86e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—STAT3—ovarian cancer	2.27e-06	1.86e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—PIK3CA—ovarian cancer	2.27e-06	1.86e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—NRAS—ovarian cancer	2.27e-06	1.85e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—MAPK3—ovarian cancer	2.27e-06	1.85e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL6—ovarian cancer	2.26e-06	1.85e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—MAPK1—ovarian cancer	2.24e-06	1.83e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MYC—ovarian cancer	2.21e-06	1.81e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—TYMS—ovarian cancer	2.21e-06	1.81e-05	CbGpPWpGaD
Afatinib—LCK—Disease—STAT3—ovarian cancer	2.19e-06	1.79e-05	CbGpPWpGaD
Afatinib—LCK—Disease—NRAS—ovarian cancer	2.18e-06	1.79e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MAPK3—ovarian cancer	2.17e-06	1.77e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MAPK1—ovarian cancer	2.16e-06	1.77e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EGFR—ovarian cancer	2.16e-06	1.77e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—MAPK1—ovarian cancer	2.16e-06	1.76e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—EGFR—ovarian cancer	2.16e-06	1.76e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—PIK3CA—ovarian cancer	2.12e-06	1.74e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—AKT1—ovarian cancer	2.12e-06	1.73e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—KRAS—ovarian cancer	2.11e-06	1.73e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MYC—ovarian cancer	2.11e-06	1.73e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—HRAS—ovarian cancer	2.1e-06	1.72e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MAPK3—ovarian cancer	2.09e-06	1.71e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—AKT1—ovarian cancer	2.09e-06	1.71e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ERBB2—ovarian cancer	2.09e-06	1.71e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MAPK1—ovarian cancer	2.07e-06	1.69e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CB—ovarian cancer	2.06e-06	1.68e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MTOR—ovarian cancer	2.06e-06	1.68e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KRAS—ovarian cancer	2.04e-06	1.67e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—KRAS—ovarian cancer	2.04e-06	1.66e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MYC—ovarian cancer	2.03e-06	1.66e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL6—ovarian cancer	2.01e-06	1.64e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ERBB2—ovarian cancer	2.01e-06	1.64e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MAPK1—ovarian cancer	1.99e-06	1.63e-05	CbGpPWpGaD
Afatinib—LCK—Disease—EGFR—ovarian cancer	1.99e-06	1.63e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTEN—ovarian cancer	1.99e-06	1.62e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MTOR—ovarian cancer	1.98e-06	1.62e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CB—ovarian cancer	1.98e-06	1.62e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCL8—ovarian cancer	1.98e-06	1.62e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—HRAS—ovarian cancer	1.97e-06	1.61e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—KRAS—ovarian cancer	1.95e-06	1.59e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PIK3CA—ovarian cancer	1.94e-06	1.59e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CDKN1B—ovarian cancer	1.93e-06	1.58e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCL8—ovarian cancer	1.91e-06	1.56e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CASP3—ovarian cancer	1.89e-06	1.55e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL2—ovarian cancer	1.89e-06	1.55e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL6—ovarian cancer	1.88e-06	1.54e-05	CbGpPWpGaD
Afatinib—LCK—Disease—KRAS—ovarian cancer	1.88e-06	1.54e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3CA—ovarian cancer	1.88e-06	1.53e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PIK3CA—ovarian cancer	1.87e-06	1.53e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CDKN1B—ovarian cancer	1.86e-06	1.52e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—AKT1—ovarian cancer	1.86e-06	1.52e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCND1—ovarian cancer	1.84e-06	1.51e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CTNNB1—ovarian cancer	1.83e-06	1.49e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CASP3—ovarian cancer	1.83e-06	1.49e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL2—ovarian cancer	1.82e-06	1.49e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—ovarian cancer	1.82e-06	1.48e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—HRAS—ovarian cancer	1.8e-06	1.47e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CA—ovarian cancer	1.79e-06	1.47e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MMP9—ovarian cancer	1.79e-06	1.46e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CAV1—ovarian cancer	1.78e-06	1.46e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTEN—ovarian cancer	1.78e-06	1.45e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCND1—ovarian cancer	1.78e-06	1.45e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CTNNB1—ovarian cancer	1.76e-06	1.44e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HRAS—ovarian cancer	1.74e-06	1.42e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—AKT1—ovarian cancer	1.74e-06	1.42e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—HRAS—ovarian cancer	1.73e-06	1.41e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CA—ovarian cancer	1.73e-06	1.41e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MMP9—ovarian cancer	1.72e-06	1.41e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL6—ovarian cancer	1.72e-06	1.41e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTEN—ovarian cancer	1.71e-06	1.4e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL6—ovarian cancer	1.66e-06	1.36e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—HRAS—ovarian cancer	1.66e-06	1.36e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL6—ovarian cancer	1.66e-06	1.35e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CG—ovarian cancer	1.62e-06	1.33e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—VEGFA—ovarian cancer	1.61e-06	1.31e-05	CbGpPWpGaD
Afatinib—LCK—Disease—HRAS—ovarian cancer	1.6e-06	1.31e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—STAT3—ovarian cancer	1.59e-06	1.3e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NRAS—ovarian cancer	1.59e-06	1.3e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—IL6—ovarian cancer	1.59e-06	1.3e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—AKT1—ovarian cancer	1.59e-06	1.3e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—VEGFA—ovarian cancer	1.55e-06	1.27e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—AKT1—ovarian cancer	1.53e-06	1.25e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—STAT3—ovarian cancer	1.53e-06	1.25e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NRAS—ovarian cancer	1.53e-06	1.25e-05	CbGpPWpGaD
Afatinib—LCK—Disease—IL6—ovarian cancer	1.53e-06	1.25e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—AKT1—ovarian cancer	1.53e-06	1.25e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAPK3—ovarian cancer	1.52e-06	1.24e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MYC—ovarian cancer	1.48e-06	1.21e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAPK3—ovarian cancer	1.47e-06	1.2e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—AKT1—ovarian cancer	1.46e-06	1.2e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAPK1—ovarian cancer	1.45e-06	1.18e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CD—ovarian cancer	1.43e-06	1.17e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MYC—ovarian cancer	1.42e-06	1.16e-05	CbGpPWpGaD
Afatinib—LCK—Disease—AKT1—ovarian cancer	1.41e-06	1.15e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CA—ovarian cancer	1.4e-06	1.15e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAPK1—ovarian cancer	1.39e-06	1.14e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EGFR—ovarian cancer	1.39e-06	1.14e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KRAS—ovarian cancer	1.37e-06	1.12e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KRAS—ovarian cancer	1.32e-06	1.08e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CA—ovarian cancer	1.26e-06	1.03e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CB—ovarian cancer	1.24e-06	1.02e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—ovarian cancer	1.21e-06	9.93e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CA—ovarian cancer	1.21e-06	9.89e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—ovarian cancer	1.17e-06	9.57e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HRAS—ovarian cancer	1.16e-06	9.49e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—AKT1—ovarian cancer	1.14e-06	9.36e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HRAS—ovarian cancer	1.12e-06	9.15e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6—ovarian cancer	1.11e-06	9.09e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTEN—ovarian cancer	1.07e-06	8.78e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6—ovarian cancer	1.07e-06	8.76e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AKT1—ovarian cancer	1.03e-06	8.38e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AKT1—ovarian cancer	9.88e-07	8.08e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CA—ovarian cancer	7.58e-07	6.19e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AKT1—ovarian cancer	6.19e-07	5.06e-06	CbGpPWpGaD
